Anaphylaxis Management (GA²LEN International Consensus 2024)
Anaphylaxis Management (GA²LEN International Consensus 2024): Suspected Anaphylaxis → Anaphylaxis Criteria Met? → ⚡ EPINEPHRINE IM - FIRST LINE → Positi...
Interactive Decision Tree
Algorithm Steps
- ▶Start
Suspected Anaphylaxis
Acute onset of multisystem involvement after exposure
- ◆Decision
Anaphylaxis Criteria Met?
Clinical diagnosis - do not delay for labs
- CRITERION 1: Skin + respiratory OR cardiovascular compromise
- CRITERION 2: ≥2 systems after likely allergen: skin, respiratory, GI, cardiovascular
- CRITERION 3: Hypotension after KNOWN allergen
- Skin signs may be absent in 10-20% of cases
- ●Action
⚡ EPINEPHRINE IM - FIRST LINE
Anterolateral thigh - DO NOT DELAY
- Adult: 0.3-0.5 mg IM (1:1000 = 1mg/mL)
- Child: 0.01 mg/kg IM (max 0.3mg)
- Auto-injector: 0.3mg (>25kg) or 0.15mg (<25kg)
- May repeat q5-15 min if needed
- THERE IS NO CONTRAINDICATION IN ANAPHYLAXIS
- ●Action
Position Patient
Supine with legs elevated (if tolerated)
- Trendelenburg if hypotensive
- Sitting if respiratory distress
- Left lateral decubitus if pregnant
- DO NOT sit/stand up suddenly
- ◆Decision
Response to Epinephrine?
Reassess within 5-15 minutes
- Improvement in BP, breathing, symptoms
- If no response, repeat epinephrine
- After 2-3 doses, consider IV epinephrine
- ●Action
Repeat Epinephrine IM
May repeat q5-15 min x 2-3 doses
- Same dose as initial
- Different injection site preferred
- Continue until response or IV access
- ◆Decision
Refractory to IM Epinephrine?
After 2-3 IM doses, consider IV epinephrine
- ⚠Warning
IV Epinephrine Infusion
For refractory anaphylaxis ONLY - requires monitoring
- Dilute: 1mg in 100mL NS (10 mcg/mL)
- Start: 1-4 mcg/min, titrate to effect
- Requires cardiac monitoring
- ICU setting preferred
- Consider glucagon if on beta-blockers
- ✓Outcome
ICU Admission
Refractory or severe - ongoing monitoring
- ●Action
Observation Period
Monitor for biphasic reaction
- Minimum 4-6 hours for mild reactions
- 8-12 hours for moderate-severe
- 24 hours if prior biphasic reaction
- Biphasic occurs in 1-20% of cases
- ●Action
Consider Labs
Do NOT delay treatment for labs
- Serum tryptase: 15min-3hr after onset
- Repeat at 24hr and baseline (2 weeks)
- Helps confirm diagnosis retrospectively
- May identify mastocytosis
- ●Action
Discharge Planning
Patient education and follow-up
- Prescribe epinephrine auto-injector (2 devices)
- Teach auto-injector technique
- Written anaphylaxis action plan
- Referral to allergist
- MedicAlert bracelet recommendation
- Return immediately if symptoms recur
- ✓Outcome
Resolved
Symptoms controlled, safe for discharge
- ●Action
Adjunct Therapies
AFTER epinephrine - never delay epinephrine for these
- IV fluids: NS bolus 1-2L (adults), 20mL/kg (peds)
- Oxygen: High-flow, maintain SpO2 >94%
- Albuterol: For bronchospasm not responsive to epi
- Antihistamines: H1 (diphenhydramine) + H2 (famotidine)
- Corticosteroids: May reduce biphasic reactions (evidence limited)
- ●Action
Call for Help
Activate emergency response/code team
- Call resuscitation team
- Note time of onset
- Identify potential trigger
- Prepare for escalation
- ●Action
Remove Trigger
If identifiable and safe to do so
- Stop IV medications/contrast
- Remove stinger (any method)
- DO NOT delay epinephrine to remove trigger
- ●Action
Consider Other Diagnoses
Vasovagal, anxiety, other causes
- Vasovagal syncope (pallor, bradycardia)
- Panic attack (no objective signs)
- Vocal cord dysfunction
- Mastocytosis/mast cell activation
- Hereditary angioedema (no urticaria)
Guideline Source
GA²LEN/EAACI Anaphylaxis Guidelines 2024: Acute Management and Care
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Epinephrine is the ONLY first-line treatment - never delay for other interventions
- IM epinephrine is preferred in most settings over IV
- Beta-blocker patients may have refractory anaphylaxis requiring glucagon
- Biphasic reactions can occur up to 72 hours - discharge education critical
- Does not cover allergen-specific immunotherapy protocols
Applicable Regions
EU: Multiple auto-injector brands available with varying doses
US: Auto-injector dosing: EpiPen 0.3mg adults, 0.15mg pediatric
International: IM adrenaline 1:1000 (1mg/mL) is standard; some areas may only have IV formulations
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Anaphylaxis Management (GA²LEN International Consensus 2024)?
The Anaphylaxis Management (GA²LEN International Consensus 2024) is a emergency clinical algorithm for Emergency Medicine. It provides a structured decision tree to guide clinical decision-making, based on GA²LEN/EAACI Anaphylaxis Guidelines 2024: Acute Management and Care.
What guideline is the Anaphylaxis Management (GA²LEN International Consensus 2024) based on?
This algorithm is based on GA²LEN/EAACI Anaphylaxis Guidelines 2024: Acute Management and Care (DOI: 10.1111/all.16321).
What are the limitations of the Anaphylaxis Management (GA²LEN International Consensus 2024)?
Known limitations include: Epinephrine is the ONLY first-line treatment - never delay for other interventions; IM epinephrine is preferred in most settings over IV; Beta-blocker patients may have refractory anaphylaxis requiring glucagon; Biphasic reactions can occur up to 72 hours - discharge education critical; Does not cover allergen-specific immunotherapy protocols. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Anaphylaxis Management (GA²LEN International Consensus 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free